This Slide: #41 of 83 |
Slide #41. Illumina, Inc. — NextBio
Acquirer:
Illumina, Inc. (NASDAQ:ILMN)
Acquiree:
NextBio
Details:
Illumina, Inc. (NASDAQ:ILMN) today announced it has signed a definitive agreement to acquire Santa Clara-based NextBio, a leader in clinical and genomic informatics. NextBio's powerful big-data platforms aggregate and analyze large quantities of phenotypic and genomic data for research and clinical applications. With the addition of NextBio's platform upon completion of the acquisition, Illumina will be able to offer customers enterprise level bioinformatics solutions that accelerate the discovery of new associations between the human genome and disease, and ultimately, enable the application of those discoveries within healthcare.
Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co.'s products and services enable the adoption of genomic solutions in research and clinical settings. Co.'s principal products, services, and technologies are: sequencing, which includes Deoxyribonucleic acid (DNA) sequencing, a process of determining the order of nucleotide bases (A, C, G, or T) in a DNA sample; arrays, which are used for a range of DNA and RNA analysis applications; consumables, which Co. has developed various library preparation and sequencing kits; and services, which provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.
ILMN SEC Filing Email Alerts Service
Open the ILMN Page at The Online Investor »
|
Open the ILMN Page at The Online Investor (in a new window) »
Free ILMN Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (2.78 out of 4) 16th percentile
(ranked lower than approx. 84% of all stocks covered)
Analysts' Target Price: ILMN Stock Forecast Based on Zacks ABR data; powered by Xignite |